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308Background: Although mitral valve repair is the recommended treatment for severe mitral regurgitation of de-
generative etiology, valve replacement remains common, particularly for complex lesions or anterior leaflet in-
volvement. We sought to characterize the feasibility and outcomes of an ‘‘all comers’’ repair strategy applied
systematically in all cases of degenerative mitral valve disease, regardless of age, complexity, or leaflet involve-
ment.
Methods: From January 2002 to December 2010, 744 consecutive patients (mean age, 58  13 years [range,
12-90]; mean LVEF, 55%  9%) with degenerative mitral valve regurgitation and prolapse (anterior leaflet:
n¼ 42, 6%; posterior leaflet: n¼ 556, 75%; bileaflet: n¼ 146, 19%) underwent mitral valve surgery. Annular,
leaflet or chordal calcification was present in 27% of cases.
Results: All patients underwent mitral valve repair and received a concomitant annuloplasty with a median ring
size of 32 mm (interquartile range, 30-36). There was 1 early valve replacement (99.9% repair rate) due to atrio-
ventricular groove bleeding and 5 late re-repairs (0.7%) due to disease progression or infective endocarditis.
In-hospital mortality and major stroke rates were 0.8% and 0.5%, respectively. Survival rates at 1 and 5 years
were 99.2%  0.3% and 97.4%  0.8%, respectively. Seven-year freedom from reoperation was 97.1% 
0.6%. The estimate of patients with<3þmitral regurgitation at 4 and 7 years was 98% and 96%, respectively,
and 95% and 91%, respectively, for<2þmitral regurgitation.
Conclusions: A systematic strategy of mitral valve repair that uses a variety of techniques allows repair of all
degenerative valves in a reference center, with good short-term outcomes and mid-term durability. Further study
is required to document the long-term efficacy of an ‘‘all comers’’ mitral valve repair strategy in degenerative
subgroups with very complex valve morphology. (J Thorac Cardiovasc Surg 2012;144:308-12)Surgical mitral valve repair is the gold standard procedure
for patients who require surgery for degenerative mitral
valve regurgitation. The American College of Cardiology
and American Heart Association guidelines for the manage-
ment of patients with valvular heart disease suggest targeted
referral to ‘‘reference centers’’ to ensure that a repair rate of
at least 90% is achieved, especially those patients who are
asymptomatic.1 Although simple posterior leaflet prolapse
is associated with very high mitral valve repair rates in
many centers,2,3 the overall repair rate for more complex
scenarios, as defined by leaflet involvement (eg, anterior or
bileaflet),4 lesion complexity (eg, significant annular calcifi-
cation, giant excess tissue), or patient comorbidities (eg,e Department of Cardiothoracic Surgery, The Mount Sinai School of Medi-
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The Journal of Thoracic and Cardiovascular Surgolder age, reoperations),5 remains less well established and
appears to be well below the guidelines-recommended
90% threshold, at least partially explaining an average mi-
tral valve repair rate of approximately 70% observed in
the Society of Thoracic Surgeons database.6 We report our
experience with a ‘‘repair for all comers’’ strategy in a con-
secutive series of patients referred for degenerativemitral re-
pair surgery, regardless of lesion(s) or patient characteristics.
MATERIALS AND METHODS
Study Population
We retrospectively identified a total of 744 consecutive patients with de-
generative mitral valve prolapse operated on for mitral regurgitation as the
primary indication by a single surgeon (D.H.A.) and his team between Jan-
uary 2002 and December 2010. Degenerativemitral valve prolapsewas con-
firmed in all patients by echocardiographic studies before the operative
exploration. There were no exclusions for etiology of degenerative disease,
such as Barlow disease or fibroelastic deficiency, or lesions, such as exten-
sive annular calcification, chordal or papillary muscle scarring, or diffuse
myxomatous degeneration. Of the 744 patients identified, 556 (75%) had
isolated posterior leaflet prolapse, 42 (6%) had isolated anterior leaflet pro-
lapse, and 146 (19%) had bileaflet prolapse. Patient demographic character-
istics, cardiac comorbidities, and other risk factors are summarized in Table
1. Mean patient age was 58  13 years (range, 12–90) years. One hundred
fifty-eight patients (21%) were70 years old.Mean left ventricular ejection
fraction was 55%  9%, and 91 patients (12%) were in New York Heart
Association functional class III or IV. Preoperative mitral regurgitation
grade, as assessed semiquantitatively by echocardiography, was moderately
severe in 48 patients (6.5%) and severe in the remaining 696 (93.5%).ery c August 2012
TABLE 1. Patient characteristics
Demographics
Age (y, range) 58  13 (12-90)
Female (no.) 263 (35.3%)
Leaflet involvement (no.)
Isolated posterior 556 (75%)
Isolated anterior 42 (6%)
Bileaflet 146 (19%)
Cardiac comorbidity
LVEF (%) 55  9
Moderate to severe MR (no.) 48 (6.5%)
Severe MR (no.) 696 (93.5%)
Previous MI (no.) 17 (2.3%)
Previous sternotomy (no.) 44 (5.9%)
Previous mitral surgery (no.) 18 (2.4%)
Atrial fibrillation (no.) 146 (19.6%)
CAD (no.) 80 (10.8%)
LVEF, Left ventricular ejection fraction;MR, mitral regurgitation;MI, myocardial in-
farction, CAD, coronary artery disease.
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Procedureswere performed through a limited incision (9-11 cm)midline
approach inmost patients (n¼ 724; 97.3%). Standard cardiopulmonary by-
pass techniques were used with predominantly central cannulation. Direct
aortic clamping and cardioplegic arrest was used in all cases, using cold
blood cardioplegia given in an antegrade and retrograde fashion. Mild sys-
temic hypothermia was used. All valves were accessed through a left atriot-
omy in the interatrial groove. Systematic valve analysis was undertaken to
identify all lesions producing valve dysfunction(s).
Valve repairs were performed by means of standard reconstructive tech-
niques (Table 2).7 Our typical approach was to sequentially repair the pos-
terior leaflet, to perform a true-sized annuloplasty with a complete
semirigid remodeling ring, and then to repair any residual prolapse of the
anterior leaflet or commissures after inspection of the line of closure during
testing with saline solution. We typically performed posterior leaflet repair
by targeted resection (quadrangular or triangular) of any prolapsing seg-
ment, reducing the posterior annular dimension if appropriate and thenTABLE 2. Reconstructive techniques
AL resection (no.) 29 (3.9%)
PL resection (no.) 633 (85%)
Triangular 139 (21.9%)
Quadrangular 479 (78.1%)
Annular plication (no.) 282 (37.9%)
PL sliding plasty (no.) 379 (50.9%)
Limited 162 (42.7%)
Extensive 183 (48.2%)
Asymmetric 34 (9.1%)
PL shortening (no.) 15 (2.0%)
PL folding plasty (no.) 13 (1.7%)
Chordal transfer (no.) 145 (19.5%)
PTFE chordoplasty (no.) 175 (23.5%)
PL flip technique (no.) 21 (2.8%)
Loop technique (no.) 16 (2.2%)
Anterolateral CP (no.) 33 (4.3%)
Posteromedial CP (no.) 92 (12.3%)
Ring size (mm, IQR) 32 (30-36)
AL, Anterior leaflet; PL, posterior leaflet; PTFE, polytetrafluoroethylene;CP, commi-
suroplasty; IQR, interquartile range.
The Journal of Thoracic and Careconstructing the posterior leaflet. In the setting of excess posterior leaflet
tissue, we typically performed a sliding leaflet plasty to reduce the height of
the posterior leaflet to 1 to 1.5 cm in all segments. In valves with minimal
tissue, the prolapse was corrected by limited triangular resections or inser-
tion of artificial polytetrafluoroethylene chordae or loops or by native
chordal transfer. Artificial chordae were also often used to reinforce the
posterior leaflet resection repair or to displace further the closure line.
We corrected anterior leaflet prolapse primarily with polytetrafluoro-
ethylene chordae or loops and chordal transfers, supplemented by triangular
resection and commissural sutures in selected cases. ACarpentier-Edwards
Physio I or II annuloplasty ring (Edwards Lifesciences LLC, Irvine, Calif)
was used in 98% of the patients. Other annuloplasty devices, such as rigid
or asymmetric rings, flexible posterior bands, and pericardial bands, were
used for specific indications such as in pediatric cases and anomalous cor-
onary anatomy. The ring size chosen was based on the surface area of the
anterior mitral leaflet. Saline solution testing and intraoperative transeso-
phageal echocardiography after weaning from cardiopulmonary bypass
were performed in all patients to control for the quality of the repair.Predischarge Echocardiography
Two-dimensional andDoppler transthoracic echocardiography examina-
tion was performed in all patients before discharge. All echocardiographic
studies were performed by using commercially available 3.75-MHz trans-
ducers and echocardiographic systems. Quantitative data promptly stored
in the institutional server were not altered throughout the study.
The presence of mitral regurgitation was prospectively assessed and its
severity was evaluated semiquantitatively by using the color Doppler regur-
gitant color jet area as previously validated.8 The grade of regurgitation was
classified as none, trace (barely detected regurgitation), mild (jet area
<4 cm2), moderate (jet area, 4-10 cm2), and severe (jet area >10 cm2).
Data Collection
Clinical variables were prospectively entered into the New York State
Department of Health (State Cardiac Advisory Committee) data registry.
The New York State Department of Health data registry represents a man-
datory, verified, peer-reviewed data-collection system that includes all
adult cardiac surgical procedures in the state of New York and records
and analyzes data in a strictly supervised and widely reported fashion.
Additionally, echocardiographic data, surgical pathology (etiology, loca-
tion of lesions, leaflet integrity, annular characteristics, chordal distribu-
tion and degeneration, and integrity of the papillary muscles), and
repair techniques were prospectively collected and entered into our de-
partmental mitral database. Further information was obtained from pa-
tient records when necessary. Information regarding long-term survival
was obtained by using the Web-based Social Security Death Index (last
update May 2011). Complete follow-up information was available in
94% of the patients. The majority of patients lost to follow-up were in-
ternational referrals. Echocardiography follow-up was performed by per-
sonal or telephone contact with the referring cardiologist. The protocol
was approved by our local institutional review board and was compliant
with the Health Insurance Portability and Accountability Act regulations
and the ethical guidelines of the 1975 Declaration of Helsinki. The ap-
proval included a waiver of informed consent.Statistical Analysis
Normally distributed continuous variables are represented as mean 
standard deviation. Nonparametric and categoric variables are represented
as median and interquartile range or as the number of patients as a percent-
age of the sample, respectively. Nonparametric survival was interrogated
and analyzed by using Kaplan-Meier survival curves. Repair durability
was obtained by echocardiographic follow-up. Mitral regurgitation grade
over time was estimated by classical Kaplan-Meier techniques. Given the
possibility of mitral regurgitation grade variation between follow-uprdiovascular Surgery c Volume 144, Number 2 309
TABLE 4. Operative outcome
In-hospital mortality (no.) 6 (0.8%)
In-hospital mortality (no., age<70) 2 (0.3%)
Morbidity (no.)
No major complications 690 (92.7%)
Major stroke 4 (0.5%)
Minor stroke 8 (1.1%)
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Dechocardiograms, interval-censored curves were constructed by using an
algorithm for nonparametric estimation. The statistical analyses were per-
formed with the use of SPSS 19 (IBM Corp, Somers, NY).
Statement of Responsibility
All authors had full access to the data and take full responsibility for
their integrity and accuracy. All authors have reviewed and agreed to the
article as written.
Respiratory failure 38 (5.1%)
Renal failure 5 (0.7%)
Sternal wound infection 5 (0.7%)
Re-exploration for bleeding 7 (0.9%)
Sepsis 8 (1.1%)
Length of stay (d, IQR) 6 (5-8)
IQR, Interquartile range.
%)
100 41 (5.5%)48 (6.5%)
4+
3+ 1+
0RESULTS
Mitral valve repair was achieved in 743 patients (99.9%).
There was 1 mitral valve replacement in a 72-year-old
woman as the result of the presence of an atrioventricular
groove hematoma recognized after weaning from bypass af-
ter mitral valve repair. The most commonly performed tech-
nique was posterior leaflet quadrangular resection (n¼ 479;
64.3%). Techniques frequently applied in conjunction with
quadrangular resection were posterior leaflet sliding plasty
(n¼ 379; 79%) and annular plication (n¼ 282; 59%). The
predominant anterior leaflet techniques were use of polyte-
trafluoroethylene neochords and chordal transfer or poste-
rior leaflet flip technique. All patients underwent
a concomitant annuloplasty as part of the repair. Adjunct
procedures included tricuspid valve repair in 62.5% of
the patients, atrial fibrillation ablation therapy in 19.6%,
coronary artery bypass grafting in 10.8%, and aortic valve
surgery in 3.0%. Any patient with more than trivial mitral
regurgitation underwent reexploration during a second run
on bypass, and this occurred in 20 cases (2.7%).
Perioperative characteristics and outcomes are reported
in Table 3. The overall in-hospital mortality rate was
0.8% (n ¼ 6) and the overall 30-day mortality rate was
0.9% (1 patient died of an apparent arrhythmia while at
home on day 13). Among patients younger than 70 years,
the in-hospital mortality rate was 0.3% (n ¼ 2). Ninety-
two percent of the patients (n ¼ 690) had a postoperative
course with no major complications. Among those patients
with postoperative complications, the 2 most common com-
plications were respiratory failure (n¼ 38; 5.1%) and over-
all stroke (n ¼ 12; 1.6%), defined as any new confirmed
neurologic deficit, regardless of severity, that did notTABLE 3. Operative details
Procedures
Mitral valve repair 743 (99.9%)
Mitral valve replacement 1 (0.1%)
Concomitant procedures (no.)
AF ablation therapy 146 (19.6%)
Tricuspid repair 465 (62.5%)
Aortic valve surgery 22 (3.0%)
CABG 80 (10.8%)
CPB time (min, IQR) 181 (147–230)
Aortic crossclamp time (min, IQR) 144 (118–191)
AF, Atrial fibrillation; CABG, coronary artery bypass grafting; CPB, cardiopulmo-
nary bypass; IQR, interquartile range.
310 The Journal of Thoracic and Cardiovascular Surgresolve within 24 hours (www.health.ny.gov/statistics/
diseases/cardiovascular). When stroke was subdivided
into major or minor on the basis of the presence of a perma-
nent neurologic deficit, major stroke rate was 0.5% (n¼ 4).
Detailed operative outcomes are reported in Table 4. The
overall median hospital stay was 6 days (interquartile range,
5–8 days). Predischarge transthoracic echocardiography
was performed in all patients. Six hundred ninety-seven pa-
tients (94.5%) had no or trace mitral regurgitation, whereas
41 patients (5.5%) had mild mitral regurgitation (Figure 1).
Overall estimated survival rate at 1 and 5 years was
99.2%  0.3% and 97.4%  0.8%, respectively. The
data compared equally with expected survival of the age-
and gender-matched general population. Seven-year
freedom from reoperation rate was 97.1%  0.6%. Five
patients (0.7%) required late reoperation for recurrent mi-
tral valve regurgitation. Two of these patients required re-
intervention within the first year after surgery because of Preoperative TTE             Predischarge TTE 
 
Pa
tie
nt
s (
0
50
Mitral Regurgitation Grade
697 (94.5%)696 (93.5%)
FIGURE 1. Perioperative transthoracic echocardiographic (TTE) assess-
ment. 0, No mitral regurgitation (MR); 1þ, mild MR; 2þ, moderate MR;
3þ, moderate to severe MR; 4þ, severe MR.
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FIGURE 2. Estimated freedoms from (A) recurrent moderate to severe or severe (3þ) mitral regurgitation (MR) and (B) moderate (2þ) mitral regur-
gitation. 0, No MR; 1þ, mild MR; 2þ, moderate MR; 3þ, moderate to severe MR; 4þ, severe MR.
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ter surgery because of progression of degenerative valve
disease (all of these patients were re-repaired). All surviv-
ing patients underwent a postoperative transthoracic echo-
cardiographic study, and late follow-up echocardiography
was available in 70% of the patients. Mean echocardiogra-
phy follow-up time was 1.5  1.1 years (range, 7-2527
days). Among those patients having follow-up echocardio-
grams, the estimate of patients with less than moderate-to-
severe or severe mitral regurgitation grades at 4 and 7 years
was 98% and 96%, respectively, versus 95% and 91%, re-
spectively, for less than moderate mitral regurgitation
(Figure 2).
DISCUSSION
We have demonstrated that it is possible to repair prac-
tically all prolapsing degenerative mitral valves, with a low
surgical risk and absence of residual significant mitral re-
gurgitation in a high-volume reference center. Our study
is unique because we have not selected patients and have
applied mitral valve repair to all comers regardless of com-
plexity of valve disease, patient age or comorbidity, and
perceived surgical risk. Most large series of contemporary
mitral valve surgery for degenerative disease in reference
centers have reported a valve replacement rate of up to
5% to 10%,9 with preferential use of valve replacement
in higher-risk groups, such as elderly patients,5 or for
more complex valve pathology, including bileaflet pro-
lapse.4 Although other series have also shown repair rates
nearing 100%, those series have been limited to a selected
group with posterior leaflet prolapse.3 Although the superi-
ority of repair relative to replacement remains controver-
sial for certain high-risk subsets, we have shown that
with a systematic approach it is possible to repair all de-
generative valves with low operative risk and good imme-
diate result.The Journal of Thoracic and CaOur mortality of less than 1%, with 92% of patients dis-
charged from the hospital without any major complications,
the absence of residual mitral regurgitation, and a repair rate
of 99% in our study satisfy the 3 key essentials for a refer-
ence mitral valve repair program, as stipulated by the
American College of Cardiology and American Heart Asso-
ciation guidelines.1 As more and more asymptomatic pa-
tients are referred for surgery, it becomes imperative that
we can reasonably assure a repair at minimal risk and
with good immediate results. Our data suggest that such
a goal is achievable with a systematic strategy of repair of
all valves by a highly specialized valve team that includes
anesthesiologists, intensivists, and cardiologists.
Our results must be interpreted with certain clarifications
or caveats in mind, some of which may limit extrapolation
and reproducibility. First, ours is a high-volumemitral valve
reference center, and this series represents a single sur-
geon’s highly specialized team results. Second, the vast ma-
jority of cases were done through a limited midline
approach because our prime focus has always been on opti-
mal access to allow application of any reconstructive tech-
nique to achieve a successful repair. Third, we have not used
a single technique to repair all valves. We do not subscribe
to the ‘‘resect or respect’’ philosophies10-12; rather, we
adapt our technique to the lesions seen in each valve,
applying both resectional and nonresectional techniques.
We believe that using a blend of techniques, rather than
a single approach, is essential if the goal is to repair all
degenerative valves. Fourth, we will take as long as
necessary to repair a valve; a quarter of our patients had
crossclamp times in excess of 3 hours. Some complex
valve scenarios, such as reoperative repair and repair in
patients with advanced Barlow disease or mitral annular
calcification, require prolonged periods of aortic
crossclamping to affect repair. Thus, to achieve a 100%
repair rate, one must be prepared to accept the occasionalrdiovascular Surgery c Volume 144, Number 2 311
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residual mitral regurgitation, other than trivial, on
postbypass transesophageal echocardiography. If there is
even mild regurgitation, then we almost always put the
patient back on bypass and perfect the repair. Finally, we
believe strongly in a lesion-based approach to mitral valve
repair and in differentiation of degenerative etiologies,13
and we hold that the key to affecting the ideal repair is tai-
loring of techniques to lesions and etiology.
Our outcome data is similar to other large series in terms
of freedom from reoperation and recurrence of significant
mitral regurgitation.2,5,9,14-19 This is significant in that
we used a ‘‘repair all comers’’ strategy (which was not
the case in all of the series describing long-term
echocardiographic data), and there was no selection of
patients based on lesion complexity, which may have
negatively impacted durability.18 Although our study was
retrospective, such a study method would not have an effect
on our key findings. Finally, because ours is a reference cen-
ter, there may be referral bias, and our patients may not be
typical of those seen in other centers. Our observation, how-
ever, is that as a national reference center, although our in-
stitution may attract substantial number of patients with
early disease, it also attracts a considerable number with ad-
vanced pathology. For example, 18 patients (2.4%) had un-
dergone previous mitral valve surgery for prolapse and
required reoperative valve repair.
We have shown that, with a systematic approach, almost
all degenerative mitral valves can be repaired safely with
excellent early results. We believe that as a specialty we
should aspire to such a goal, arguably for all patients but es-
pecially for the asymptomatic cohort. We do understand
that there is a definite volume–outcome relationship within
mitral valve surgery,20 such that these goals, although likely
now achievable in most reference centers, would be unreal-
istic for most surgeons who do few mitral valve repairs. Our
data, therefore, add additional emphasis to the guideline
recommendation to refer patients with mitral valve prolapse
to specialized reference surgical centers if there is a doubt
about the probability of repair in a particular patient.1 Our
data also adds to the debate as to whether volume, perfor-
mance, and outcome criteria should be used to designate
a minimum standard for centers undertaking degenerative
mitral valve repair,21 particularly in young or asymptomatic
patients in the future.22,23References
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